BioWorld

Feb. 14, 2006

View Archived Issues

Greenwood Planning More Time Spent On Capitol Hill

Read More

Affymax Partners Anemia Drug In Japan For $102M

Less than a month after Affymax Inc. started the fourth Phase II trial of its lead product, Hematide, to treat anemia, the company signed a partnership deal in Japan worth up to $102 million. (BioWorld Today) Read More

Replidyne Gets $50M Up Front Through Forest Collaboration

Read More

Novacea’s IPO Seeks $75M To Fund Late-Stage DN-101

Read More

Avastin Study Suspended Because Of Patient Deaths

Read More

Caliper Buying Xenogen: $80M In Stock, Warrants

Read More

Other News To Note

Read More

Clinic Roundup

Read More